The Analysts Set Intercept Pharmaceuticals Inc. (ICPT) Price Target at $177.62

The Analysts Set Intercept Pharmaceuticals Inc. (ICPT) Price Target at $177.62

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has been given a consensus recommendation of “Buy” by the twenty analysts that are currently covering the company. Four investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $174.31.

ICPT has been the topic of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $239.00 price target on shares of Intercept Pharmaceuticals in a report on Sunday, September 25th. Cowen and Company reaffirmed a “buy” rating and set a $225.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, November 2nd. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. JMP Securities reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Sunday, November 6th. Finally, Leerink Swann reaffirmed a “positive” rating and set a $159.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, October 14th.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 115.80 on Thursday. The stock’s market cap is $2.87 billion. The stock has a 50 day moving average of $106.61 and a 200-day moving average of $136.08. Intercept Pharmaceuticals has a 52 week low of $89.76 and a 52 week high of $177.93.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.82) by $0.23. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $4.77 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The firm’s revenue was up 1051.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.10) earnings per share. Equities research analysts predict that Intercept Pharmaceuticals will post ($15.64) earnings per share for the current fiscal year.

In other Intercept Pharmaceuticals news, insider Rachel Mcminn sold 816 shares of the business’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $103.92, for a total transaction of $84,798.72. Following the transaction, the insider now owns 12,916 shares in the company, valued at $1,342,230.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lisa Bright sold 249 shares of the business’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $113.60, for a total transaction of $28,286.40. Following the transaction, the insider now owns 18,209 shares in the company, valued at approximately $2,068,542.40. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ICPT. The Manufacturers Life Insurance Company bought a new stake in shares of Intercept Pharmaceuticals during the third quarter worth about $114,000. KBC Group NV raised its stake in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 779 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 370 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares in the last quarter. Institutional investors and hedge funds own 82.40% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Related posts

Leave a Comment